Anti-Norovirus, Capsid (Clone NORO-323) – Purified No Carrier Protein
Anti-Norovirus, Capsid (Clone NORO-323) – Purified No Carrier Protein
Product No.: N267
- -
- -
Product No.N267 Clone NORO-323 Target Capsid ⋅ Norovirus Formats AvailableView All Product Type Recombinant Monoclonal Antibody Isotype Human IgG1 Applications ELISA , N |
- -
- -
Antibody DetailsProduct DetailsReactive Species Norovirus Expression Host HEK-293 Cells Immunogen Sequenced from PBMCs from a donor who had recovered from a naturally-occurring norovirus infection. Product Concentration ≥1.0 mg/ml Purity ≥90% monomer by analytical SEC and SDS-Page Formulation This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -80°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2 – 8° C Wet Ice Additional Applications Reported In Literature ? ELISA, N Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity NORO-323 activity is directed against norovirus capsid. Background Norovirus is a highly contagious pathogen known for its ability to cause acute gastroenteritis, which is a major health concern worldwide1. The virus's low infectious dose means minor exposure can lead to infection. Prolonged shedding by hosts and environmental resilience further heighten transmission risks through prolonged surface contamination2. It is the leading cause of foodborne diseases, exclusively infecting humans3. Timely implementation of infection prevention measures is crucial for outbreak control2. Studies have found a variety of antibodies that have a broad reactivity for noroviruses, including single-chain antibodies4, monoclonal antibodies5, and a cross-reactive monoclonal antibody6. These antibodies have the potential to be used in diagnostic applications as they have been shown to detect norovirus antigens in clinical samples. Studies have also found that the reactivity of these antibodies can vary depending on the norovirus strain7. NORO-323 is a monoclonal antibody designed to target norovirus, showcasing a promising profile for broad cross-reactivity and neutralization across multiple norovirus genotypes. This clone stands out for its potential applications in enhancing norovirus diagnostics and contributing to the development of a much-needed vaccine, marking a significant step forward in controlling and understanding norovirus infections8. Antigen Distribution Norovirus infects and replicates in immune cells, including macrophages,
dendritic cells, and B cells, as well as in enteroendocrine cells in the human gut. Research Area Infectious Disease . Nosocomial . Viral . IVD Raw Material References & Citations1. Inns T, Harris J, Vivancos R, Iturriza-Gomara M, O’Brien S. Community-based surveillance of norovirus disease: a systematic review. BMC Infectious Diseases. 2017;17(1):657. 2. Norovirus | Clinical Microbiology Reviews. Accessed March 22, 2024. https://journals.asm.org/doi/10.1128/cmr.00075-14 3. Schneider KR, Goodrich RM, Mahovic MJ, Shukla R. Preventing Foodborne Illness: Norovirus: FSHN0518/FS129, 10/2005. EDIS. 2005;2005(12). 4. Huang W, Samanta M, Crawford SE, et al. Identification of human single-chain antibodies with broad reactivity for noroviruses. Protein Eng Des Sel. 2014;27(10):339-349. 5. Yoda T, Suzuki Y, Terano Y, et al. Precise Characterization of Norovirus (Norwalk-Like Virus)-Specific Monoclonal Antibodies with Broad Reactivity. Journal of Clinical Microbiology. 2003;41(6):2367-2371. 6. Li X, Zhou R, Tian X, Li H, Zhou Z. Characterization of a cross-reactive monoclonal antibody against Norovirus genogroups I, II, III and V. Virus Res. 2010;151(2):142-147. 7. Ajami NJ, Barry MA, Carrillo B, et al. Antibody Responses to Norovirus Genogroup GI.1 and GII.4 Proteases in Volunteers Administered Norwalk Virus. Clinical and Vaccine Immunology. 2012;19(12):1980-1983. 8. Alvarado G, Salmen W, Ettayebi K, et al. Broadly cross-reactive human antibodies that inhibit genogroup I and II noroviruses. Nat Commun. 2021;12(1):4320. Technical ProtocolsCertificate of Analysis |
Formats Available
- -
- -
Prod No. | Description |
---|---|
N267 |
